Scientists and physicians discussed advances in targeted therapies and immunotherapies, as well as the lessons COVID-19 research has taught to cancer researchers.

by Kevin McLaughlin

Two immune checkpoint inhibitors are now approved for treatment of some people with advanced breast cancer, but trial results have raised some questions.

by Anna Goshua

The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.

by Anna Azvolinsky

An analysis of cancer patients who were infected with the coronavirus and treated at Memorial Sloan Kettering Cancer Center in New York City suggests certain risk factors may predict more severe COVID-19.

by Anna Azvolinsky

Following the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.

by Marci A. Landsmann

Patients with advanced cancer often go to rehabilitation facilities after a hospital stay in hopes of gaining the strength for further treatment, but the majority do not go on to receive additional cancer therapy, a study reports.

by Ashley P. Taylor

Immune checkpoint inhibitors can be effective treatments for elderly people with some types of advanced cancer, but more information is needed on their risks and benefits in this group.

by Emma Yasinski

Drug developers behind currently approved checkpoint inhibitors discuss the pros and cons of competition in the field.

by Kate Yandell

Some researchers believe that immunotherapy occasionally causes cancer to grow faster, a phenomenon dubbed hyper-progression.

by Kate Yandell

Medical oncologist Leisha A. Emens discusses the significance of the first U.S. Food and Drug Administration approval of an immunotherapy treatment for breast cancer.

by Anna Azvolinsky